To keep up to date with news from this category use our
Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris
Leiden, The Netherlands (October 21, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that preliminary results of the Phase I study of its HIV vaccine were...
Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development
Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
Durham, NC and Paris, France- October 21, 2009 -- Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing...
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...
Sernova's Cell Pouch System(tm) and Sertolin(tm) Preclinical Efficacy Presented at Leading International Islet Transplant Conference
LONDON, ONTARIO--(Oct. 20, 2009) - Sernova Corp. (TSX VENTURE:SVA - News) is pleased to provide a summary of results of islet transplantation studies related to its Cell Pouch System(TM) and Sertolin(TM) technologies...
TcLand Expression Launches An International, Multicenter Clinical Validation Study
Nantes, France, October 13, 2009 - TcLand Expression SA, a global leader in the field of gene expression biomarkers in immunology, today announced the launch of the KARE study (Kidney Allograft REjection). This will be...
BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad
Paris, October 12, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency...
Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Rockville, Md. - October 12, 2009--- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it...
FDA Approves Berinert to Treat Abdominal Attacks, Facial Swelling Associated With Hereditary Angioedema
October 9, 2009 -- The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic...
ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm Antigen Test
UNION CITY, Calif., Oct. 8 -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis instruments for the medical, research and veterinary markets, announced today that it has...
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
BERKELEY, Calif. - October 8, 2009 -- Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating...
A New Model for Studying Meganuclease-Based Therapeutic Approaches Featured in International, Peer-Reviewed Journal Blood
Paris, October 8, 2009 - Cellectis S.A. (Alternext: ALCLS), the French genome engineering company, announced that the results of experiments conducted by Dr. Jean-Pierre de Villartay's group from the French National...
Panenza
Lyon, France - October 8, 2009 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that a single dose of influenza A (H1N1) 2009 monovalent vaccines, Panenza
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
October 07, 2009 -- Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription...
Vical's TransVax(TM) CMV Vaccine Elicits Long-Term Immune Responses in Phase 2 Trial
SAN DIEGO, Oct. 7, 2009 -- Vical Incorporated (Nasdaq:VICL) announced today that the company's TransVax(TM) cytomegalovirus (CMV) vaccine continued to demonstrate an overall increase in cellular immune responses...
STEMCELL Technologies Inc. Introduces MethoCult
Vancouver, British Columbia -October 07, 2009-- STEMCELL Technologies Inc., a Vancouver-based life sciences company, announces the launch of MethoCult
FDA Marks 100th HIV/AIDS Drug Authorized for Purchase Under PEPFAR
October 6, 2009 -- The U.S. Department of Health and Human Services (HHS) today marked today marked the recent approval of the 100th antiretroviral drug in association with the President's Emergency Plan for AIDS Relief...
Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety and Immunogenicity in Clinical Trial
SAN DIEGO---Oct. 5, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical...
Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety and Immunogenicity in Clinical Trial
SAN DIEGO-- October 5, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic...
Sequella Receives American Recovery and Reinvestment Funding through the NIH
Rockville, Md. - October 5, 2009- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a...
CombinatoRx-Derived Combination Drug Candidate, Prednisporin, Acquired by Sanofi-Aventis Through Proposed Acquisition of Fovea Pharmaceuticals
CAMBRIDGE, Mass.--Oct. 5, 2009-- CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that its ophthalmic collaborator, Fovea Pharmaceuticals SA, has entered into a proposed acquisition with Sanofi-Aventis. A...
Vical Presents Positive Preclinical Results with Vaxfectin(R)-Formulated, Peptide-based Cancer Vaccine
BOSTON, Sept. 24, 2009-- Vical Incorporated (Nasdaq:VICL) announced today the presentation of encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company's Vaxfectin(R)...
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
RICHMOND, Calif., Sept 23, 2009 -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to...
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
PITTSBURGH, September 16, 2009 -- Mylan Inc. (NASDAQ: MYL) today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug...
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
VILLA GUARDIA (COMO), Italy, August 19, 2009 -- Gentium S.p.A. (NASDAQ: GENT) today announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and...
Tarix Pharmaceuticals receives IND to treat HIV patients with persistently low CD4 counts
Brookline, MA, March 21, 2008 -- Tarix Phamaceuticals announced that it has received an approval of an IND to begin a Phase Ia dose escalation study to evaluate the safety of TXA127 in HIV patients maintained on HAART...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
